In the Cellular Immunotherapy and Transplantation Program at Virginia Commonwealth University Massey Cancer Center, scientists are pursuing a cross-collaborative effort that could potentially change the way cellular immunotherapies such as stem cell transplantation and CAR T-cell therapies are performed. This grassroots research is funded primarily through VCU Massey pilot grants, and it is culminating in a first-of-its-kind body of work that provides a detailed quantitative view of how the immune system responds to cellular therapies.
Research conducted by scientists at VCU Massey Cancer Center found that a novel combination of drugs is effective against acute myeloid leukemia (AML) in preclinical models. The findings, recently published in the journal Cancer Research, could lead to new and improved treatments for AML and other hematologic malignancies.
Palliative care consultations administered within three days of admission are linked to shorter hospitalizations and significant cost savings for chronically ill adults, according to a large meta-analysis study involving researchers at VCU Massey Cancer Center.
A new study led by scientists at VCU Massey Cancer Center has shown that an experimental drug known as AZ32 selectively sensitizes brain tumors to radiation and significantly extends the survival of mouse models with human glioblastoma multiforme (GBM), the most common and deadly form of brain cancer.
Thousands of women with breast cancer may be spared chemotherapy, thanks to landmark study co-authored by Massey physician-researcher
Seventy percent of women with the most common type of newly diagnosed breast cancer can now be identified and safely skip chemotherapy, according to the results of a landmark 12-year clinical research study.